Raymond James raised the firm’s price target on Doximity (DOCS) to $75 from $65 and keeps an Outperform rating on the shares. Doximity’s Q1 results showed an impressive top-line beat and above consensus outlook, with a conservative guidance for the back half of the year, the analyst tells investors in a research note. The firm is encouraged by commentary on the mid-year buying and the impact of the customer portal.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $65 from $62 at Wells Fargo
- Doximity price target raised to $59 from $50 at Canaccord
- Doximity’s Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns
- Doximity Reports Strong Q1 Earnings with Revenue Growth
- Closing Bell Movers: Expedia, TripAdvisor jump on Q2 earnings beats